New Drug Regimen Approval for Pancreatic Cancer
A new drug regimen for certain types of pancreatic cancer received approval from the FDA, showing significant improvements in survival rates and response rates. The drug, Onivyde, is administered via IV infusion every two weeks and is considered a useful new tool in conjunction with other chemotherapies.
Key Points
- Onivyde is administered via IV infusion every two weeks
- Approval based on a randomized, controlled trial with 770 patients
- Considered a useful new tool in conjunction with other chemotherapies
Pros
- Significant improvements in survival rates and response rates
- New treatment option for metastatic pancreatic adenocarcinoma
Cons
- Expensive compared to existing standard medication
- Common side effects include diarrhea, nausea, vomiting, fatigue, and weight loss